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Background:  ECCO  essential  requirements  for quality  cancer  care  (ERQCC)  are  checklists  and  explanations
of  organisation  and  actions  that  are  necessary  to give  high-quality  care  to patients  who  have  a  speciﬁc
tumour  type.  They  are  written  by European  experts  representing  all disciplines  involved  in  cancer  care.
ERQCC  papers  give  oncology  teams,  patients,  policymakers  and  managers  an  overview  of  the  elements
needed  in  any  healthcare  system  to provide  high  quality  of care  throughout  the  patient  journey.  Refer-
ences  are  made  to clinical  guidelines  and other  resources  where  appropriate,  and  the  focus  is on  care  in
Europe.
Sarcoma: essential  requirements  for  quality  care
• Sarcomas  –  which  can be classiﬁed  into  soft  tissue  and  bone  sarcomas  –  are  rare,  but  all  rare  can-
cers  make  up  more  than  20%  of  cancers  in Europe,  and  there  are  substantial  inequalities  in  access  to
high-quality  care. Sarcomas,  of  which  there  are many  subtypes,  comprise  a particularly  complex  and
demanding  challenge  for  healthcare  systems  and  providers.  This  paper  presents  essential  requirements
for  quality  cancer  care  of  soft tissue  sarcomas  in  adults  and  bone  sarcomas.
• High-quality  care  must  only  be carried  out  in specialised  sarcoma  centres  (including  paediatric  cancer
centres)  which  have  both  a core  multidisciplinary  team  and  an  extended  team  of allied professionals,  and
which are  subject  to quality  and  audit  procedures.  Access  to  such  units  is far  from  universal  in  all  European
countries.
• It is  essential  that,  to meet  European  aspirations  for high-quality  comprehensive  cancer  control,
healthcare  organisations  implement  the  requirements  in this  paper,  paying  particular  attention  to mul-
tidisciplinarity  and  patient-centred  pathways  from  diagnosis  and  follow-up,  to  treatment,  to  improve
survival  and  quality  of  life  for  patients.
Conclusion:  Taken  together,  the information  presented  in  this  paper provides  a comprehensive  description
of  the essential  requirements  for establishing  a  high-quality  service  for soft  tissue  sarcomas  in  adults  and
bone sarcomas.  The  ECCO  expert  group  is aware  that  it  is not  possible  to propose  a ‘one  size  ﬁts  all’
system  for  all countries,  but  urges  that  access  to  multidisciplinary  teams  is guaranteed  to all  patients
with  sarcoma.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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As a rare group of cancers, many people with sarcomas are
already referred to specialist centres, but this again is far from
universal. All patients must have access to the care pathways and6 E. Andritsch et al. / Critical Reviews in
reamble
ECCO essential requirements for quality cancer care (ERQCC)
re checklists and explanations of organisation and actions that are
ecessary to give high-quality care to patients who have a speciﬁc
umour type.
They are primarily organisational recommendations, not clinical
uidelines, and are intended to give policymakers and managers,
ncology teams and patient groups a non-technical overview of the
lements needed in any healthcare system to provide high-quality
are throughout the patient journey. References are made to clinical
uidelines and other resources where appropriate, and the focus is
n care in Europe.
The foundation of this ECCO requirements series is the concept
f quality, which has become increasingly important in all aspects
f healthcare, as the population has an increasing number of older
eople needing care, as many new and complex treatments come
nto use, and as more pressure is put on using resources effectively.
olicymakers and patients need to know that their healthcare
orkforce, technology and facilities are conﬁgured optimally for
ach illness. In this context, improving quality means delivering
ancer care that is timely, safe, effective and efﬁcient; puts the
atient at the centre of care; and gives all people equal access to
igh-quality care.
The structure of the ECCO ERQCC series is the same for each
umour type:
Introduction: why we need cancer quality frameworks
Key facts and challenges associated with the tumour type, from
diagnosis to treatment, to follow-up
Organisation of care: an overview of the patient pathway and
overall requirements to deliver care
Multidisciplinary working: in more detail, the requirements for
core and ‘expanded’ teams involved in the patient pathway
Measurement and accountability: quality assurance and audit,
patient involvement and access to information.
ssential requirements for quality cancer care: sarcoma
ummary points
Sarcomas – which can be classiﬁed into soft tissue and bone sar-
comas – are rare, but all rare cancers make up more than 20% of
cancers in Europe, and there are substantial inequalities in access
to high-quality care. Sarcomas, of which there are many subtypes,
comprise a particularly complex and demanding challenge for
healthcare systems and providers. This paper presents essential
requirements for quality cancer care of soft tissue sarcomas in
adults and bone sarcomas.
High-quality care must only be carried out in specialised sarcoma
centres (including paediatric cancer centres) which have both a
core multidisciplinary team and an extended team of allied pro-
fessionals, and which are subject to quality and audit procedures.
Access to such units is far from universal in all European countries.
It is essential that, to meet European aspirations for high-quality
comprehensive cancer control, healthcare organisations imple-
ment the requirements in this paper, paying particular attention
to multidisciplinarity and patient-centred pathways from diag-
nosis and follow-up, to treatment, to improve survival and quality
of life for patients.logy/Hematology 110 (2017) 94–105
1. Introduction
1.1. Why  we  need quality frameworks
There has been a growing emphasis on driving up quality in
cancer organisations, given that there is wide agreement that much
care is not comprehensively accessible, not well coordinated and
not based on current evidence. This is the starting point of a report
by the US Institute of Medicine (IOM) in 2013 (Levit et al., 2013),
which is blunt in describing a ‘crisis in cancer care delivery’, as the
growing number of older people will mean rising cancer incidence
and numbers of survivors, while there are pressures on workforces
amid rising costs of care and complexity of treatments.
Not least, the IOM notes that the few tools currently available
for improving the quality of cancer care − quality metrics, clinical
practice guidelines and information technology − are not widely
used and all have serious limitations.
An assessment of the quality of cancer care in Europe was  made
as part of the ﬁrst EU Joint Action on Cancer, the European Part-
nership for Action Against Cancer (EPAAC, http://www.epaac.eu),
which reported in 2014 that there are important variations in ser-
vice delivery between and within countries, with repercussions in
quality of care. Factors such as waiting times and provision of opti-
mal  treatment can explain about a third of the differences in cancer
survival, while cancer plans, for example a national cancer plan
that promotes clinical guidelines, professional training and quality
control measures, may  be responsible for a quarter of the survival
differences.
EPAAC paid particular attention to the importance of providing
multidisciplinary care for each tumour type, going as far as issuing
a policy statement (Borras et al., 2014) that emphasised the impor-
tance of team working, as cancer care is undergoing a ‘paradigm
shift’ from a disease-based approach to a patient centred one, in
which increasingly more attention is paid to psychosocial aspects,
quality of life, patients’ rights and empowerment, comorbidities
and survivorship. EPAAC further focused on the establishment of
networks of expertise in regions where it is not possible to estab-
lish comprehensive centres. Another important outcome of EPAAC
is the development of the European Standards of Care for Chil-
dren with Cancer (European Society for Paediatric Oncology, 2009),
which support this paper where children and adolescents are con-
cerned.
The EU Joint Action on Cancer Control (CANCON, http://www.
cancercontrol.eu), which replaced EPAAC from 2014, is also focus-
ing on quality of cancer care and is due to publish in 2017 the
European Guide on Quality Improvement in Comprehensive Cancer
Control.
Countries have been concentrating expertise for certain tumour
types in dedicated centres, or units, such as for childhood and rare
cancers, and most compreherehensive cancer centres have teams
for the main cancer types. For common adult tumours, however,
at the European level there has been widespread effort to establish
universal, dedicated units only for breast cancer, following several
European declarations that set a target of the year 2016 for care of
all women and men  with breast cancer to be delivered in specialist
multidisciplinary centres. While this target has been far from met
(Cardoso et al., 2016), the view of ECCO’s essential requirements
expert group is that the direction of travel is for all tumour types
to adopt the principles of such dedicated care.
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ultidisciplinary teams described in this document, and which are
ubject to same approach to auditing, quality assurance and accred-
tation of a ‘unit’ that is emerging in breast cancer.
. Soft tissue sarcomas in adults and bone sarcomas: key
acts and challenges
.1. Key facts
Sarcomas are cancers that are classed as ‘rare’, which means they
have a prevalence (people living with the diseases) of fewer than
ﬁve cases in a population of 10,000, and an incidence of fewer
than six in 100,000 a year (Rare Cancers Europe, http://www.
rarecancerseurope.org/About-Rare-Cancers).
Sarcomas are among the largest groups of rare cancers. There are
two main categories: soft tissue and bone sarcomas.
© Soft tissue sarcomas are cancers that occur in many parts of
the body. They are malignancies of mesenchymal (supporting)
tissues and are named by the site or type of tissue affected.
Gastrointestinal stromal tumour (known as GIST, and one of
the most frequent sarcomas), affects the wall of the gastroin-
testinal tract and is usually put into a separate category to
other sarcomas. The incidence of adult soft tissue sarcomas
is about 4 per 100,000 a year in Europe and they comprise
more than 80% of sarcomas. They are distinct from childhood
soft tissue sarcomas − the latter are common types of rare
paediatric cancers and have different characteristics, treat-
ment protocols and guidelines and so are not included in this
document; see the European Society for Paediatric Oncology
(SIOPE, https://www.siope.eu) and the SIOPE strategic plan
(Vassal et al., 2016) for more information.
Bone sarcomas are primary cancers that arise from bone. They are
less common than adult soft tissue sarcomas, comprising about
15% of sarcomas in Europe. The most common types are osteosar-
coma and Ewing sarcoma, which have the highest incidence in
adolescents and young adults, and are included in this document
as treatment strategies are similar to those for adults. The most
common adult bone sarcoma is chondrosarcoma. Other bone sar-
comas include undifferentiated pleomorphic sarcomas of bone
(UPS), chordomas and giant cell tumours of bone. The European
Standards of Care for Children with Cancer also apply to bone
sarcomas in children and adolescents.
There are dozens of types of adult soft tissue sarcomas and
adult/child bone sarcomas, with widely different patterns of stage
at diagnosis, prognosis and treatments. The Eurocare-5 survival
study (Baili et al., 2015) gives a 60% 5 year survival for cancers
classed as arising from ‘soft tissue’ and just over 50% for those
classiﬁed as arising from ‘bones and cartilages’, indicating that
as whole, sarcomas are in the mid- to upper-level in 5 year sur-
vival rates. Detailed data have been published for the ﬁrst time in
2013 by RARECARE (http://www.rarecare.eu), which carries out
surveillance of rare cancers in Europe. It found that the incidence
of all type of sarcoma is about 6 in 100,000, with 28,000 new cases
a year in Europe; in 2008, 280,000 people were estimated to be
alive following a diagnosis. Details of 5 year survival of various
types and sites of sarcoma are given in a RARECARE paper (Stiller
et al., 2013).
The cause of most sarcomas is unknown. Half of patients have an
excess of pathogenic (and potentially aetiological) germline vari-
ants (Ballinger et al., 2016). Risk factors for soft tissue sarcomas
include age (about one third are diagnosed in people aged 65 and
older, and this group has the lowest survival rates for most sar-
comas), previous radiation treatment, previous cancers, and rare
genetic conditions that are present in families. Kaposi’s sarcoma
is caused by a virus and mainly seen in people with HIV infection,logy/Hematology 110 (2017) 94–105 97
and should be distinguished from other sarcomas. Osteosarcoma
in older people may  be associated with Paget’s disease.
2.2. Diagnosis and treatment
• Symptoms of adult soft tissue sarcomas include lumps and pain.
Diagnosis is by imaging and biopsy. Common symptoms of bone
sarcomas are pain, swelling and problems with movement.
• A diverse range of treatments are carried out for the many types
of sarcoma (Casali, 2016). Surgery is the main treatment for most
sarcomas, and can include limb-sparing operations or amputa-
tion where, infrequently, this is the only option to eliminate the
cancer. Chemotherapy and radiotherapy may also be used before
surgery (to devitalise tumours) and after (to prevent recurrence)
depending on the histology and the risk of relapse. Several tar-
geted therapies are used in sarcomas, notably imatinib to treat
GIST.
2.3. Challenges in sarcoma care
2.3.1. Access to specialists
• An overall challenge for sarcomas is the availability of experts
and multidisciplinary groups and networks. This is often the case
with rare diseases such as sarcomas, and some smaller countries
may  even lack a specialised sarcoma unit.
2.3.2. Diagnosis
• The rarity of sarcomas, the large number of types, and often vague
symptoms mean that most primary care doctors will infrequently
encounter a person with sarcoma. Further, a benign diagnosis
may  outnumber the diagnosis of sarcoma by a factor of 100. This
can result in late diagnoses and delayed referrals.
• Radiologists and pathologists specialising in sarcomas play a cru-
cial role in the correct diagnosis of sarcomas, but are usually based
only in a few centres. Surgical biopsies not performed by experts
can lead to complications, impairments to subsequent treatments
and possibly tumour spread. A study from 2012 (Ray-Coquard
et al., 2012) concluded that more than 40% of ﬁrst histological
diagnoses were modiﬁed at second reading, possibly resulting in
different treatment decisions, and the ECCO expert group stresses
that diagnosis must only take place in sarcoma centres or paedi-
atric cancer centres with expertise in treating sarcomas (Beishon,
2013).
• In sum, there can be profound implications for a patient not diag-
nosed at a sarcoma centre, such as missing the chance of a timely
diagnosis of a potentially curable disease, and being spared more
extensive surgery.
2.3.3. Treatment
• Surgery for sarcomas can be difﬁcult and needs highly experi-
enced surgeons to achieve the best outcomes. A study from 2004
(Ray-Coquard et al., 2004) showed that more than 50% of soft
tissue sarcoma patients are not correctly operated on.
• After some time with little change in drug treatments (mainly
chemotherapy) for metastatic sarcomas, there are now several
new systemic and targeted drugs for adult soft tissue sarcomas,
either approved or that show promise in clinical trials, following
advances in understanding the molecular biology of sarcomas,
and medical oncologists face increasingly complex treatment
choices. As about half of patients with intermediate and high-
grade sarcomas will have a recurrence, their best management is
crucial.
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Osteosarcoma, Ewing sarcoma and bone UPS have a high risk of
metastatic spread, particularly to the lungs and to distant bones,
and treatment aimed at local control of the primary tumour is
rarely curative unless integrated into a multidisciplinary treat-
ment concept with multi-agent chemotherapy. Up to two thirds
of patients may  become long-term, disease-free survivors, pro-
vided they receive high-quality multidisciplinary care.
.3.4. Inequalities
People with sarcomas in Central and Eastern Europe have lower
5 year survival rates than those in other countries. This is partic-
ularly true of bone sarcomas and GIST, and the RARECARE paper
notes that outcomes for bone sarcomas, in particular, depend on
multidisciplinary teams, which may  be lacking in a number of
countries, and not only in Central and Eastern Europe (Stiller et al.,
2013).
.3.5. Young people
While paediatric cancer units are available in many countries,
units with expertise and appropriate facilities to meet the needs
of adolescents and young adults (AYA) are fewer, but are also
required.
.3.6. Survivorship
Although the number of people in Europe who have had treat-
ment for sarcoma is small compared with those who  have had
common cancers, survivors can have a wide range of needs,
including rehabilitation and surveillance for late toxicities.
. Organisation of care
Essential requirements for the organisation of sarcoma care are:
Cancer care pathways that cover the entire patient journey
Timeliness of care
Minimum case volumes for sarcoma centres
Multidisciplinary team working including core and extended
groups of professionals, in dedicated sarcoma centres or units
Audit and quality assurance of outcomes and care processes
Education, policies to enrol patients in clinical trials, patient infor-
mation.
These topics are outlined in the following sections, with ref-
rence to national and European resources and clinical practice
uidelines, where appropriate.
.1. Sarcoma units/centres
It is essential that treatment is organised in units or centres that
specialise in sarcomas, often termed ‘reference centres’, which
are also often part of networks at an appropriate geographical
level (regional, national and supranational). Diagnosis and many
treatment procedures must only be performed in the sarcoma
centre, although professionals at a centre can also be part of an
extended multidisciplinary team (MDT) covering other institutes
and networks.
Treatment of childhood sarcomas is usually organised in paedi-
atric cancer centres that also treat other paediatric cancers. For
the purpose of this paper, the term ‘sarcoma centre’ also applies
to paediatric cancer centres.
It is essential that the sarcoma centre and the members of the
MDT have a signiﬁcant annual number of cases and that the core
MDT  has members with sarcomas as their only, or one of their
primary, interest(s). On the basis of existing evidence, the expertlogy/Hematology 110 (2017) 94–105
group recommends that for an institution to be considered as a
sarcoma centre it should treat at least 100 new sarcoma patients
(both soft tissue and bone) a year, although a threshold will
depend on the structure of sarcoma networks in a region or coun-
try and the distribution of expertise. Guidance from the National
Institute for Health and Care Excellence (NICE) in England and
Wales says that MDTs managing either soft tissue sarcoma or
bone sarcoma should manage the care of at least 100 new patients
a year (100 soft tissue and 50 bone sarcomas if the MDT  manages
both types), reﬂecting the more centralized nature of the UK’s
health system (National Institute of Health and Care Excellence,
2006). Note that owing to the rarity of paediatric cancer in general
and bone sarcoma in particular, minimum case volumes are nec-
essarily different between adult and paediatric treatment centres.
• RareCareNet, a European Union information network on rare can-
cers, has set out criteria for a sarcoma referral centre, and which
are discussed in a paper, ‘Accreditation for centres of sarcoma
surgery’ (Sandrucci et al., 2016).
3.2. Care pathways and timelines
• Care for sarcoma patients must be organised in pathways that
cover the patient’s journey from their point of view rather than
that of the healthcare system, and pathways must correspond to
current national and European evidence-based clinical practice
guidelines on diagnosis, treatment and follow-up. (The Euro-
pean Pathway Association deﬁnes a care pathway as “a complex
intervention for the mutual decision making and organisation
of care processes for a well-deﬁned group of patients during a
well-deﬁned period”. This broad deﬁnition covers terms such as
clinical, critical, integrated and patient pathways that are also
often used. See http://e-p-a.org/care-pathways). One source of
information on care organisation is again NICE – it has published
documents including a manual on improving sarcoma out-
comes (National Institute of Health and Care Excellence, 2006), a
pathway (http://pathways.nice.org.uk/pathways/sarcoma), and a
quality standard (see section on auditing, quality assurance and
accreditation). Pathways for soft tissue and bone sarcomas are
different, and there are examples of such pathways (e.g. NHS Lon-
don and South East Sarcoma Network, http://www.lsesn.nhs.uk/
sarcoma.html).
• Primary care practitioners, general surgeons and medical oncol-
ogists are often referrers of those with suspected sarcoma and
need timely access to reference centres. The maximum time for
an appointment for suspected adult cancer in England and Wales
is 2 weeks, for example. NICE also recommends that children
and young people with suspected bone sarcoma on an x-ray are
referred within 48 h for an appointment with a specialist, and also
within 48 h for unexplained bone pain or swelling.
• Reasonable times to report a diagnosis of sarcoma and the oppor-
tunity to start treatment are crucial to timely treatment and to the
wellbeing of patients. For example guidelines in the Netherlands
state that the maximum time for diagnostic and staging proce-
dures is 3 weeks, and the maximum time from ﬁrst appointment
to ﬁrst treatment is 6 weeks, but shorter times should be aimed
for.
• After a diagnosis, it must be clear to the patient which profes-
sional is responsible for each step in the treatment pathways and
who  is following the patient during the journey (usually called a
case manager or patient navigator) (Albreht et al., 2015). In many
countries, case managers during the main stages of treatment are
cancer nurses.• Follow-up and survivorship are major issues in sarcoma. Typi-
cally, care pathways include surveillance for cancer recurrence
but patients often have to seek help elsewhere for long term
side-effects of treatment, by going to both acute and commu-
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nity facilities. Continuity and integration of all care by specialists
must be implemented as gaps in long-term care can cause much
distress.
.3. European networks and societies
Sarcoma centres must also participate in European sarcoma care
nd research networks and societies. Such organisations play a cru-
ial role in pooling expertise in all rare cancers. In sarcoma, research
roups include the Soft Tissue and Bone Sarcoma Group at EORTC
European Organisation for Research and Treatment of Cancer),
nd the Euro Ewing Consortium; and professional societies include
he European Musculo-Skeletal Oncology Society (EMSOS) and the
onnective Tissue Oncology Society (CTOS).
A challenge is sustainability of networks, and the rare cancer
ommunity has been lobbying for funding, including from the new
uropean Reference Networks (ERNs) (Wagstaff, 2016) (Blay et al.,
016a). Applications for ERNs on rare cancers, including adult sar-
omas and childhood sarcomas, are currently being reviewed by
he European Commission; quality of care requirements will be an
mportant part of the work of these networks. The EU Joint Action
n Rare Cancers will also support the creation of ERNs in the EU.
.4. The multidisciplinary team
Treatment strategies for all patients must be decided on,
lanned and delivered as a result of consensus among a core mul-
idisciplinary team (MDT) that comprises the most appropriate
embers for the particular diagnosis and stage of cancer, patient
haracteristics and preferences, and with input from the extended
ommunity of professionals. The heart of this decision-making pro-
ess is normally a weekly or more frequent MDT  meeting where
ll patients are discussed with the objective of balancing the rec-
mmendations of clinical guidelines with the often formidable
omplexity of the individual sarcoma patient.
To properly treat sarcomas it is essential to have a core MDT  of
edicated health professionals from the following disciplines:
Radiology/imaging
Interventional radiology
Pathology
Surgery
Radiotherapy
Medical and paediatric oncology
Nursing.
This core MDT  meets to discuss:
All cases after diagnosis and staging to decide on optimal treat-
ment
All cases prior to local treatment (surgery, radiotherapy or
chemotherapy (Gronchi et al., 2016))
Patients after major treatment, usually surgery, to decide on fur-
ther treatment and follow-up
Patients with a recurrence during follow-up, or where changes to
treatment programmes are indicated and have multidisciplinary
relevance and/or planned deviations from clinical practice guide-
lines.
In addition, sarcoma radiologists should participate in meetings
here discrepancies between radiology and histology, as well as
istakes, are discussed. When there is a discrepancy between a
adiologist not based at the centre and the ﬁnal diagnosis, feed-
ack should be provided in an open and non-judgmental manner,
elping to raise standards among non-sarcoma radiologists.logy/Hematology 110 (2017) 94–105 99
Healthcare professionals from the following disciplines must
also be available whenever their expertise is required (the
‘expanded’ MDT):
• Nuclear medicine
• Oncology pharmacy
• Geriatric oncology
• Psycho-oncology
• Palliative care
• Rehabilitation and survivorship.
There is also an increasing sub-group of sarcomas that have a
genetic predisposition. It may  be necessary soon to add a clini-
cal geneticist to the expanded MDT  to discuss options for genetic
testing and its results with patients and their families.
All decisions have to be documented in an understandable man-
ner, and should become part of the patient records. It is good
practice for decisions taken during MDT  meetings to be monitored,
and deviations reported back to the MDT  where there are problems.
It is essential that all relevant patient data, such as pathology
reports, meet quality standards and are available at the time of the
MDT  meeting.
4. Disciplines within the core MDT
4.1. Radiology/imaging
Radiology/imaging plays a critical role in diagnosing, staging and
follow-up of sarcomas and personalised treatment. The role of the
radiologist is to perform and interpret relevant imaging procedures
as part of the diagnosis of sarcomas.
Essential requirements:
• Sarcoma centres must have radiologists who  have signiﬁcant
expertise in the diagnosis, staging and follow-up of sarcomas
• Radiologists must have access to imaging modalities required for
diagnosing and staging of sarcomas (e.g. ultrasound, radiographs,
CT, MRI)
• The radiologist must know when to refer a patient to nuclear
medicine. In that case (referral for bone scintigraphy, SPECT/CT
or PET/CT), nuclear medicine physicians and radiologists must
liaise to allow joint patient management, reading and reporting
• Sarcoma radiologists must collaborate with other specialist radi-
ologists (e.g. ENT radiologists and paediatric radiologists), as
sarcomas affect a wide variety of organs and ages
• Imaging and histopathology ﬁndings should be discussed
together before making a diagnosis, to minimise diagnostic dis-
crepancies. This is of particular importance in bone tumours and
tumour-like lesions where conditions such as myositis ossiﬁcans
may  be misinterpreted as osteosarcoma on histopathology, or in
cases where the obtained biopsy may  not be representative of
the entire lesion (Nuovo et al., 1992) (Noebauer-Huhmann et al.,
2015) (SLICED, 2007)
• For bone sarcomas and other sarcomas in children, adolescents
and young adults, radiologists need experience with these age
groups.
4.2. Interventional radiology
Interventional radiology plays an important role in the diagno-
sis of sarcomas. Indeed, image-guided percutaneous core needle
biopsy is crucial in the delivery of a safe and efﬁcient sarcoma
service, and is the preferred biopsy technique in the diagnosis of
sarcomas. The role of the interventional radiologist is to:
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Perform image-guided percutaneous core needle biopsy of sup-
posed sarcoma and to perform biopsy in case of unclear hepatic
or pulmonary lesions (Yang and Damron, 2004)
Provide expertise and support for combined therapies in patients
with metastatic disease (e.g. transarterial treatments or ablative
therapies)
Perform appropriate minimally-invasive therapies according to
the MDT’s decision.
Essential requirements:
Biopsies must be performed in sarcoma centres
Interventional radiologists performing image-guided biopsies for
a sarcoma centre must have training and experience (Lee et al.,
2012), have access to appropriate imaging equipment and must
implement the WHO  Surgical Safety Checklist
Interventional radiologists must work with the MDT to plan the
biopsy to avoid the risk of ‘contamination’ of other compart-
ments, which may  signiﬁcantly hamper surgical resection
The interventional radiologist must discuss the role and propose
use of local ablative techniques for treating liver, lung or bone
metastases not amenable to, or combined with, surgery or radio-
therapy (Koelblinger et al., 2014) (Falk et al., 2015) (Jiang et al.,
2016)
For bone sarcoma and other sarcoma biopsies in children, adoles-
cents and young adults, interventional radiologists need sarcoma
experience with these age groups.
.3. Pathology
Specialist pathologists are needed for diagnostic accuracy of sar-
omas given their rareness, the large number of histotypes and
he morphological overlap between benign and malignant cases.
s diagnosis drives treatment options, a dedicated and experi-
nced pathologist must be in the core MDT  from the start. In
everal countries there are panels of experienced pathologists that
ave substantial impact on diagnostic accuracy and subsequent
reatment results (Jansen-Landheer et al., 2009). Adequate sam-
ling is needed for histology. While open biopsies offer more
issue sometimes needed for molecular and immunohistochemical
echniques, most centres use thick core needle biopsies to obtain
aterial for histology both for soft tissue and bone tumours (The
SMO/European Sarcoma Network Working Group, 2014a,b).
Essential requirements:
The pathologist must establish a correct diagnosis according to
the 2013 WHO  classiﬁcation, and in case of malignancy predict
tumour behaviour by stating the tumour grade. In soft tissue
tumours this is done according to the FNLCC criteria (Neuville
et al., 2014) and, when needed, by additional molecular tech-
niques (Hogendoorn et al., 2004)
Access to a molecular biologist must be guaranteed (not neces-
sarily on site) and material for molecular testing must be set aside
and preserved according to guidelines
There must be a double-reading of the slides not only when
the biopsy was done outside a sarcoma centre (which must be
avoided where possible) but also if the biopsy was done in the
sarcoma centre.
.4. SurgerySurgery is the mainstay of the treatment of sarcomas, espe-
ially in primary disease. All non-metastatic adult-type primary
arcomas are removed (resected) when possible as part of front-logy/Hematology 110 (2017) 94–105
line treatment; surgery alone can cure more than half of adult-type
sarcoma patients (Gronchi et al., 2015) (Le Cesne et al., 2014). For
patients with metastatic disease and local recurrence, surgery can
also be an important part of treatment. Surgical margins are a major
prognostic factor concerning the risk of local recurrence in limbs,
and en-bloc resection is a determinant prognostic factor of over-
all survival in retroperitoneal sarcoma (RPS). The experience of the
surgeon is a prognostic factor of overall survival in RPS, and surgery
at a sarcoma centre achieves better margins (Blay et al., 2016b).
The role of the chief surgeon at a sarcoma centre is to:
• Coordinate diagnostic procedures, surgery and perioperative care
• Perform appropriate surgery as decided in the MDT.
Essential requirements:
• Surgery must only be performed in a sarcoma centre by surgical
oncologists with signiﬁcant expertise in sarcomas
• A sarcoma surgeon should carry out at least 3–4 procedures
a month (30–40 a year) and they must participate in sarcoma
groups and meetings at national and/or international level. It is
good practice for activity and outcomes to be published, and in
future the expert group recommends that education/fellowship
in sarcoma management is required
• Visceral surgical oncologists must be able to perform multi-
visceral resections, including digestive and urologic organs in
one bloc; plan (with a multidisciplinary surgical team) which
organs/structures to sacriﬁce, with the potential for local con-
trol weighed against the potential for long-term dysfunction; and
have expertise in procedures such as full-thickness thoracoab-
dominal wall, diaphragmatic and major vascular resection and
reconstruction. All these abilities may  also be available among
multidisciplinary surgical teams, but the sarcoma surgeon must
be able to plan collaborations when necessary
• Bone sarcomas must be operated on by a specialist surgeon. In
most cases this is an orthopaedic surgeon, but can also be a
paediatric surgeon or another surgeon depending on the sar-
coma location. These surgeons must have signiﬁcant experience
in bone sarcoma treatment
• The sarcoma centre should treat at least 100 patients per year
if the MDT  manages both bone and soft tissue sarcoma patients.
Owing to the rarity of paediatric cancer in general and bone sar-
coma in particular, this volume requirement does not apply to
paediatric centres treating bone sarcomas in children, adoles-
cents and young adults. The structure of sarcoma networks in
a region or country and the distribution of expertise is another
parameter inﬂuencing volume requirements
• There must be an intensive care unit in sarcoma centres
• Access to a plastic/reconstructive surgeon must be guaranteed
• For bone sarcoma and other sarcomas in children, adolescents
and young adults, surgeons need sarcoma experience with these
age groups. This is particularly important for bone sarcoma
surgery in young people who  have not reached skeletal maturity.
4.5. Radiotherapy
As described in the NCCN and ESMO guidelines (neo-)adjuvant
radiotherapy should be considered for non-metastatic sarcomas
of intermediate and high grade malignancy; it is much less rel-
evant for low grade sarcomas (von Mehren et al., 2016) (The
ESMO/European Sarcoma Network Working Group, 2014b) (Haas
et al., 2012) (O’Sullivan et al., 2013). The role of the radiation
oncologist is to determine and prescribe the most suitable dose
of radiation to deliver in a particular case, and the method and
technique by which this will be achieved. Except for Ewing sar-
comas, chordomas and chondrosarcomas (derived from the base of
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kull, spine and sacrum), radiotherapy is rarely used in bone sarco-
as  as the only curative treatment, owing to radioresistance which
equires higher doses that increase side-effects. It is important to
ote that the quality of radiotherapy is signiﬁcantly associated with
ocal control, and quality assurance is mandatory for these types of
ancer (Donaldson et al., 1998).
Essential requirements:
Radiation oncologists must have expertise in sarcoma subtypes
and especially the probability of local recurrence per subtype
They must know the indications and contra-indications for
(neo)adjuvant and deﬁnitive radiotherapy, counsel patients prior
to surgery on the choice of neoadjuvant or adjuvant therapy, and
inform patients about acute and late side-effects, and interven-
tions to prevent them from happening or worsening
The centre must have access to latest technologies such as IMRT,
IMAT and stereotactic (body) radiotherapy, with a state of the art
mould room to make personalised immobilisation devices
The centre must be able to perform (daily) online setup veriﬁ-
cation protocols and to react according to deviations observed.
Prospective quality assurance protocols must be in place
The centre must organise treatment at a proton/heavy ion radio-
therapy centre if needed (DeLaney and Haas, 2016)
For bone sarcomas and other sarcomas in children, adolescents
and young adults, radiation oncologists need sarcoma experience
with these age groups.
.6. Medical and paediatric oncology
Medical therapy is needed in most patients with advanced dis-
ase for all sarcomas, in virtually all patients with osteosarcoma
nd Ewing sarcoma, and in many high-risk soft tissue sarcoma and
IST patients with localized disease (The ESMO/European Sarcoma
etwork Working Group, 2014b) (Neuville et al., 2014). It is also
ften used as front-line therapy before surgery. Medical therapy is
ecoming highly variable depending on the pathologic and molec-
lar characteristics of the patient. Tumour response to medical
herapy may  present peculiar patterns, especially in bone sarco-
as, GIST and with some molecularly targeted therapies in soft
issue sarcomas.
Given the rarity of sarcomas, and that medical therapy often
akes many months to administer, medical oncologists should be
repared to work in health networks that care for adult patients
lose to their home.
Essential requirements:
Medical therapy must be planned and administered by a medi-
cal oncologist, or a paediatric oncologist for young patients, from
the beginning of the patient’s journey, in collaboration with the
MDT  and closely following imaging (with regard also to uncon-
ventional patterns of tumour response)
The medical/paediatric oncologist must have specialised exper-
tise in sarcomas with experience from working in a sarcoma
reference centre and/or a sarcoma reference network. Sarcomas
must be a major component of their work
Medical/paediatric oncologists must be involved in sarcoma
clinical research collaborative groups at a national and/or inter-
national level.
.7. NursingNurses are the professionals who spend most time caring for
eople with sarcoma, and require a range of roles, owing to the
iversity of tumour types and contexts of care. They need spe-logy/Hematology 110 (2017) 94–105 101
cialised knowledge and skills to nurse people receiving complex,
multi-modal sarcoma treatments, which have a high degree of mor-
bidity (Samuel, 2018).
Essential requirements:
• Nurses must conduct holistic nursing assessments to ensure
safe, personalised and age-appropriate nursing care, and pro-
vide patient information and support to promote self-efﬁcacy
throughout the patient journey
• Nurses must provide intensive care following surgery; care for
patients who have had tissue conservation, bone ﬁxation, limb
salvage or surgical reconstruction; care for patients receiving
high-dose chemotherapy; and care for patients receiving adju-
vant radiation therapy, including brachytherapy (Lahl et al., 2008)
• They must alleviate symptoms of sarcoma (e.g. pain, fatigue,
spinal cord compression); prevent or manage side-effects
of treatment (e.g. radiation-induced skin injury, change in
body appearance and/or function); and care for patients with
treatment-related complications (e.g. wound infection, ﬂap
necrosis, neutropenic sepsis, acute kidney injury)
• When acting as case managers, nurses must coordinate care with
health professionals outside the core MDT, including rehabilita-
tion, psychosocial, fertility and palliative care services (Prades
et al., 2015).
5. Disciplines within the expanded MDT
5.1. Nuclear medicine
Bone scintigraphy, SPECT/CT with various radiotracers, and
PET/CT with 18F FDG and 18F-FNa may  be indicated in certain sar-
comas (musculoskeletal soft tissue sarcomas, bone sarcomas and
GIST) for prognosis, staging, treatment response evaluation, and
restaging (to conﬁrm limited or resectable disease before curative
intent therapy, and for local recurrence and metastases) (Nanni
et al., 2009) (Gabriel and Rubello, 2016).
The role of the nuclear medicine physician is to oversee all
aspects of bone scintigraphy, SPECT/CT and PET/CT for patients who
require these procedures, including indications, multidisciplinary
algorithms and management protocols.
Essential requirements:
• Nuclear medicine physicians with expertise in PET must be avail-
able to the MDT. In 2016, most European hospitals have access to
PET/CT technology but it should preferably be on-site, be less than
10 years old and ready for integration in radiation treatment plan-
ning, and have integrated PACS/RIS and updated workstations
• Conventional nuclear medicine must also be available
• Nuclear medicine must be able to perform daily veriﬁcation pro-
tocols and to react accordingly. Quality-assurance protocols must
be in place. An option for ensuring the high quality of PET/CT scan-
ners is provided by the European Association of Nuclear Medicine
(EANM) through EARL accreditation (Boellaard et al., 2015)
• For bone sarcomas and other sarcomas in children, adolescents
and young adults, nuclear medicine physicians need sarcoma
experience with these age groups.
5.2. Geriatric oncologyAs a third of soft tissue sarcoma patients are aged 65 or more,
the MDT  must have access to geriatricians with oncology experi-
ence. While chronological age should not be a reason to withhold
1  Onco
e
r
•
•
•
•
•
5
p
t
•
•
•
•
5
s
(
m
h
p
a
p
a
l02 E. Andritsch et al. / Critical Reviews in
ffective therapy, goals may  vary signiﬁcantly according to age and
equires expert geriatric input.
The role of the geriatric oncologist is to:
Ensure that older patients are screened for frailty
Coordinate recommendations to other specialists about the need
for personalised treatment for frail patients.
Essential requirements:
Geriatric oncologists must ensure all older patients are screened
with a simple risk-assessment frailty screening tool (Decoster
et al., 2015) (Huisman et al., 2014) with whenever possible an
estimation of life expectancy to help prioritise medical inter-
ventions (e.g. ePrognosis colorectal screening survey. http://
cancerscreening.eprognosis.org/screening)
A geriatric oncology team (including geriatricians and other spe-
cialists) must be available for all frail patients and their evaluation
discussed in MDT  meetings to offer personalised treatment
Geriatric oncologists must ensure the early integration of pal-
liative care plans or geriatric interventions, especially for frail
patients.
.3. Oncology pharmacy
Oncology pharmacy plays a critical role in the care of sarcoma
atients, given the importance of systemic treatment. The role of
he oncology pharmacist is to:
Liaise with the medical oncologist and/or paediatric oncologist to
discuss pharmaceutical treatment
Supervise the preparation of oncology drugs.
Essential requirements:
Oncology pharmacists must work closely with medical/paediatric
oncologists. They must have experience with interactions with
other drugs; experience with dose adjustments based on age,
liver and kidney function; and knowledge of complementary and
alternative medicines. Oncology pharmacists must comply with
the European QuapoS guidelines (European Society of Oncology
Pharmacy, 2014)
Oncology drugs must be prepared in the pharmacy or designated
area which meets the criteria pharmacies must comply with and
dispensing must take place under the supervision of the oncology
pharmacist.
.4. Psycho-oncology
About 30% of sarcoma patients suffer from anxiety at diagno-
is and during treatment and 20% suffer from clinical depression
Paredes and Canavarro Simões, 2010) (Paredes et al., 2012). Treat-
ent can seriously affect quality of life, especially for those who
ave major operations on limbs. Concerns about body image are
articularly high in young people with bone sarcomas. Appropri-
te psychological interventions such as mindfulness training and
sycho-educative programmes are needed for the main sarcoma
ge groups. Supporting family members is also essential, particu-
arly for relations of children, adolescents and young adults.
The role of the psycho-oncologist is to:logy/Hematology 110 (2017) 94–105
• Ensure that psychosocial distress (National Comprehensive
Cancer Network, 2003), and other psychological disorders and
psychosocial needs, are identiﬁed by screening, and are consid-
ered by the MDT
• Promote effective communication between patients, family
members and healthcare professionals.
• Support patients and family members to cope with multifaceted
disease effects
• Facilitate the reintegration of sarcoma survivors in school, work,
social and family environments through evidence-based psy-
choeducational interventions.
Essential requirements:
• Patients must have access to a self-administered psychological
assessment tool (‘distress thermometer’)
• Psychosocial care must be provided at all stages of the disease and
its treatment for patients and their families and must be present
to ensure comprehensive cancer care
• In paediatric cancer, it is recommended that psychosocial support
includes play therapy and access to schooling.
5.5. Palliative care
About 30–50% of patients with sarcomas die within 5 years
from diagnosis, and there is an increasing need for palliative care
throughout the disease trajectory, not only at end-of-life but at
diagnosis and during cancer treatments to manage distressing clin-
ical complications and symptoms and to improve the quality of life
of patients and their families (Temel et al., 2010) (Hui et al., 2015)
(Quill and Abernethy, 2013) (Coindre et al., 2001). Palliative care, as
deﬁned by the World Health Organization, applies not only at end
of life but throughout cancer care (see http://www.who.int/cancer/
palliative/deﬁnition/en).
The role of the palliative specialist is to:
• Be responsible for specialist palliative care and recommenda-
tions to other specialists regarding general palliative care (e.g.
symptom control)
• Be available at diagnosis and the early phase of treatment
• Identify patients in need for palliative care through systematic
assessment of distressing physical, psychosocial and spiritual
problems
• Provide early palliative care in conjunction with cancer spe-
ciﬁc treatments, treat disease and treatment-related distressing
symptoms such as pain and dyspnoea, and offer psychosocial and
spiritual care
• Provide support for family members
• Provide end-of-life care together with primary care palliative care
providers.
Essential requirements:
• There must be a palliative care team that provides expert outpa-
tient and inpatient care
• The palliative care team must include specialist physicians and
nurses, working with social workers, chaplains, psychotherapists,
physiotherapists, occupational therapists, dieticians, pain spe-
cialists and the psycho-oncology team• The palliative care unit must collaborate with community pallia-
tive care teams
• All patients with severe symptoms or suffering, or patients with
metastatic disease and short life expectancy (under a year), irre-
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spective of the cancer treatment plan, must also be in the care of
palliative care team
For bone sarcomas and other sarcomas in children, adolescents
and young adults, the palliative care team needs experience with
these age groups.
.6. Rehabilitation and survivorship
Rehabilitation and survivorship plans are often omitted in the
lanning of clinical and psychosocial care for patients and their
amilies. They must be integrated into pathways to ensure the best
ossible care continues beyond initial treatment (Stubbleﬁeld et al.,
013) (Berg et al., 2016) (Scott et al., 2013). A multidisciplinary
eam involving clinicians, nurses, psychologists and physiothera-
ists must discuss with patients how their functioning will change
uring and after treatment, and options for improvement.
Essential requirements:
Many cancer patients are living longer after their treatment, but
they are often not well-informed about late-effects and how their
lives could be affected. Patients and their families must be bet-
ter informed about potential late-effects and how these can be
monitored and tackled
Where the limbs are involved, it is important to identify rehabil-
itation needs related to movement and daily activities, and plan
physical training accordingly
Return to school or work is important for many cancer patients
and has both ﬁnancial and wellbeing beneﬁts. Employers must
have early discussions about ﬂexibility in returning to work, such
as changing job duties and working hours, including for families
of patients with paediatric cancer
Rehabilitation and survivorship of cancer must be integrated into
national cancer plans.
. Other essential requirements
.1. Patient involvement, access to information and transparency
Patients must be involved in every step of the decision-making
process. Their satisfaction with their care must be assessed
throughout the patient care pathway. Patients must be offered
relevant and understandable information to help them appreci-
ate the process that will be followed with their treatment from
the point of diagnosis. They must be supported and encouraged to
engage with their health team to ask questions and obtain feed-
back on their treatment wherever possible. Children need to be
involved in an age-appropriate manner and their parents/carers
should be included in the process as appropriate.
It is also essential that sarcoma patient support organisations
are involved whenever relevant throughout the patient pathway.
These groups work to:
© Improve patients’ knowledge and ability to take decisions
© Secure access to innovative therapies and improve quality of
treatment
© Support sarcoma research, such as by being involved in the
design of clinical trials
© Advocate at national health policy level.
The Sarcoma Patients EuroNet Association (SPAEN) (www.
arcoma-patients.eu) is an international network of national
arcoma support and advocacy groups. Childhood Cancer Interna-
ional (CCI) is the largest patient support organisation for childhood
ancer and has a European committee, CCI Europe (http://www.
hildhoodcancerinternational.org/cci-global-network/europe).logy/Hematology 110 (2017) 94–105 103
• Conclusions on each case discussion must be made available to
patients and their primary care physician. Advice on seeking sec-
ond opinions must be supported.
• Cancer healthcare providers must publish on a website, or make
available to patients on request, data on centre/unit performance,
including:
© Information services they offer
© Waiting times to ﬁrst appointment
© Pathways of cancer care
© Numbers of patients and treatments at the centre
© Number of operated patients at the centre
© Clinical outcomes
© Patient experience measurements
© Incidents/adverse events.
6.2. Auditing, quality assurance and accreditation
• The expanded MDT  must meet at least once a year to review the
activity of the previous year, discuss changes in protocols and
procedures, and improve the performance of the unit/centre.
• To properly assess quality of sarcoma care, three categories of
outcomes must be measured and collected in a database at the
level of the specialised sarcoma centre, and regionally and/or
nationally:
© Clinical outcomes
© Process outcomes
© Patient-reported outcomes (PROs).
• Data measured and collected varies from one country to another
but it is recommended that the following outcome data are sys-
tematically measured and collected:
© 5 year survival rate
© 5 year local recurrence rate
© 5 year local control rate
© Complications
© % of patients discussed in the MDT  before any treatment
© % of postoperative patients discussed in the MDT.
The expert group also recommends that centres develop perfor-
mance measurement metrics based on the essential requirements
in this paper.
• The ECCO expert group recommends that further attention must
be given to patient reported outcome measures (PROMs), to not
only agree on which tools should be used, but also to use PROs
more systematically as part of discussions and evaluation within
the MDT.
To ensure appropriate, timely and high-quality care, a quality
management system (QMS) must be in place. It must involve clini-
cal care, strategic planning, human resource management, training
etc. The QMS  must be accountable at an institutional management
level and be based on written and agreed documentation such as
guidelines, protocols, patient pathways, structured referral systems
and standard operating procedures (SOPs).
The QMS  must ensure the continuity of care for patients, the
involvement of patients in cancer care pathways, and the report-
ing of patient outcomes and experience. As part of a QMS, an
effective data management and reporting system, and an internal
audit system, are necessities. Where available, external national
audit and certiﬁcation systems are to be followed. The ECCO
expert also strongly recommends participation in international
accreditation programmes (e.g. Organisation of European Cancer
Institutes (OECI) accreditation, http://oeci.selfassessment.nu/cms)
(Wind et al., 2016).
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.2.1. Country examples
The National Institute of Health and Care Excellence (NICE) in
England and Wales has published a quality standard for sarcoma
(National Institute of Health and Care Excellence, 2015). It aims to
ensure that people with sarcoma are treated by healthcare pro-
fessionals with experience and expertise in treating sarcoma, and
that people with sarcoma are informed about their condition,
receive appropriate and timely advice, and can access relevant
services. Statements in the standard cover referrals and treat-
ment by MDTs, among others.
The German Cancer Society operates a certiﬁcation system
for cancer centres that includes sarcomas (see https://www.
krebsgesellschaft.de/gcs/german-cancer-society/certiﬁcation.
html).
France has clinical and pathology networks (NetSarc and RRePS)
that offer patients a means to make a systematic diagnosis of
soft tissue sarcoma and help to access treatment in a specialised
centre (Honoré et al., 2015).
.3. Education and training
It is essential that each sarcoma centre provides professional
linical and scientiﬁc education on the disease and that at least one
erson is responsible for this programme. Healthcare profession-
ls working in sarcoma must also receive training in psycho-social
ncology, palliative care, rehabilitation and communication skills,
ailored to patient age where relevant. Such training must also be
ncorporated into specialist postgraduate and undergraduate cur-
iculums for physicians, nurses and other professionals. Nurses
orking in sarcoma centres should undertake post-qualiﬁcation
ducation and training about providing holistic care for people
eing treated for sarcoma throughout the patient journey.
.4. Clinical research
Centres treating sarcoma must have clinical research pro-
rammes (either their own research or as a participant in
rogrammes led by other centres). The research portfolio should
ave both interventional and non-interventional projects and
nclude academic research.
The MDT  must assess all new patients for eligibility to take part
n clinical trials at the centre or in research networks. For sar-
oma, centres should have at least 10% of all patients included
n their research projects or in research performed in other cen-
res. Researchers at other centres should be considered as part of
he expanded MDT  for at least annual discussion of clinical trial
articipation.
In paediatric oncology, participation in therapy-optimising
tudies is a standard of care in most countries. Children, ado-
escents, and young adults in all countries should have access
o national or international multicentre studies, and accelerated
ccess to innovative therapies if their disease progresses.
Older adults are currently underrepresented in cancer clin-
cal trials despite having a disproportionate burden of disease
Kaz´mierska, 2013). Strategies to increase the participation of older
dults, adolescents and young adults in clinical trials must be
mplemented and trials designed to take their needs into account.
. Conclusion
Taken together, the information presented in this paper pro-
ides a comprehensive description of the essential requirements
or establishing a high-quality service for soft tissue sarcomas in
dults and bone sarcomas. The ECCO expert group is aware that it
s not possible to propose a ‘one size ﬁts all’ system for all countries,logy/Hematology 110 (2017) 94–105
but urges that access to multidisciplinary teams is guaranteed to all
patients with sarcoma.
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